

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

|  |                              |
|--|------------------------------|
| SUBMISSION TYPE:   | NEW ASSIGNMENT               |
| NATURE OF CONVEYANCE:  | ASSIGNMENT                   |
| <b>CONVEYING PARTY DATA</b>  |                              |
| Name   | Execution Date               |
| Adenosine Therapeutics, LLC  | 08/20/2008                   |
| <b>RECEIVING PARTY DATA</b>  |                              |
| Name:  | PGxHealth, LLC               |
| Street Address:  | One Gateway Center           |
| Internal Address:  | Suite 702                    |
| City:  | Newton                       |
| State/Country:   | MASSACHUSETTS                |
| Postal Code:   | 02458                        |
| <b>PROPERTY NUMBERS Total: 1</b>   |                              |
| Property Type  | Number                       |
| Application Number:  | 12501750                     |
| <b>CORRESPONDENCE DATA</b>   |                              |
| Fax Number:  | (617)607-9200                |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> |                              |
| Phone:   | 617-449-6500                 |
| Email:   | lmargolis@mccarter.com       |
| Correspondent Name:  | McCarter & English, LLP      |
| Address Line 1:  | 265 Franklin Street          |
| Address Line 4:  | Boston, MASSACHUSETTS 02110  |
| ATTORNEY DOCKET NUMBER:  | 118553-11202                 |
| NAME OF SUBMITTER:   | A. Jacqueline Wizeman, Ph.D. |

Total Attachments: 9  
 source=118553\_11202\_AdenosinetoPGxHealth#page1.tif  
 source=118553\_11202\_AdenosinetoPGxHealth#page2.tif  
 source=118553\_11202\_AdenosinetoPGxHealth#page3.tif

**501386277**

**PATENT  
 REEL: 025533 FRAME: 0150**

**CH \$40.00 12501750**

source=118553\_11202\_AdenosinetoPGxHealth#page4.tif  
source=118553\_11202\_AdenosinetoPGxHealth#page5.tif  
source=118553\_11202\_AdenosinetoPGxHealth#page6.tif  
source=118553\_11202\_AdenosinetoPGxHealth#page7.tif  
source=118553\_11202\_AdenosinetoPGxHealth#page8.tif  
source=118553\_11202\_AdenosinetoPGxHealth#page9.tif

## PATENT ASSIGNMENT AGREEMENT

WHEREAS, ADENOSINE THERAPEUTICS, L.L.C., a Virginia limited liability company (hereinafter referred to as “Assignor”) has agreed that it will assign to Assignee (defined below) all of its right, title and interest in and to all of the patents and patent applications listed or described in Schedule 1 attached hereto and incorporated herein by reference; and

WHEREAS, PGX HEALTH, LLC, a Delaware limited liability company (hereinafter referred to as “Assignee”) and a wholly-owned subsidiary of Clinical Data, Inc., a Delaware Corporation, is desirous of acquiring all rights, title, and interest in and under the Intellectual Property (as defined below).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors and assigns all of its right, title and interest to those patents and applications identified as such in Schedule 1 hereto, and (i) all U.S. and foreign patents and patent applications that claim priority to such identified patents and applications and all U.S. and foreign patents and applications to which such identified patents and applications relate or claim priority, directly or indirectly, (ii) any provisionals, continuations, continuations-in-part, divisionals, reissue applications, re-examinations, substitutions, extensions, foreign counterparts, Patent Cooperation Treaty applications, or derivatives of any of the foregoing, both foreign and domestic, which have or may be filed, (iii) all patents (including, but not limited to reissues and re-examinations) which may be granted on the applications set forth in (i) and (ii) above, and (iv) all patentable inventions, in the U.S. and every foreign country, described or embodied in any of the foregoing, (the “*Intellectual Property*”) and does hereby authorize and request the Commissioner of Patents to issue U.S. patents to the above-mentioned Assignee in accordance with the terms of this assignment document. Such full and exclusive rights shall include, without limitation, the right to sue upon and otherwise enforce the Intellectual Property and to recover all past damages and other potential relief arising from infringement of the Intellectual Property assigned by this agreement.

ASSIGNOR HEREBY AUTHORIZES Assignee and its attorney of record to insert on this assignment document, including Schedule 1, any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office and/or any foreign patent office for recordation of this document and Assignor hereby authorizes and requests the United States Patent and Trademarks Office to issue said Letter Patents in accordance with this agreement.

UPON SAID CONSIDERATION, Assignor conveys to Assignee the right to make application in its own behalf for protection of the Intellectual Property in the U.S. and countries foreign to the U.S. and to claim under the Patent Cooperation Treaty, the International Convention and/or other international arrangement for any such application the date of any earlier U.S. application (or any other application on the invention) to gain priority with respect to other applications.

IN WITNESS WHEREOF, Assignor has caused one of its authorized representatives to hereunder set his hand on the date shown below and Assignee has caused one of its officers to hereunder set his hand on the date shown below to signify its acceptance of this assignment.

[Signature page follows]

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment Agreement to be signed by its duly authorized officer as of August 20, 2008.

**ASSIGNOR**

**ADENOSINE THERAPEUTICS, L.L.C.**

By: [Signature]

Name: Robert S. Capon

Title: Chief Executive Officer

**ASSIGNEE**

**PGX HEALTH, LLC**

By: Cogenics, Inc. (its Sole Member)

By: \_\_\_\_\_

Name: Caesar J. Belbel


Title: Executive Vice President, Chief  
Legal Officer and Secretary

~~Commonwealth~~  
State of Virginia )  
City of Charlottesville ) ss.

On August 20th, 2008, before me, Joseph Milton, Notary Public, personally appeared Robert S. Capon, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

[Signature]  
Notary ID 7101431  
Signature of Notary Public



My Commission Expires: June 30, 2011

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment Agreement to be signed by its duly authorized officer as of August \_\_\_\_, 2008.


**ASSIGNOR**

**ADENOSINE THERAPEUTICS, L.L.C.**

By: \_\_\_\_\_  
Name: Robert S. Capon  
Title: Chief Executive Officer

**ASSIGNEE**

**PGX HEALTH, LLC**

By: Cogenics, Inc. (its Sole Member)  
By:   
Name: Caesar J. Belbel  
Title: Executive Vice President, Chief Legal Officer and Secretary

State of Massachusetts )  
County of Middlesex ) ss.

On August 7, 2008, before me, Kathleen Pozelet, Notary Public, personally appeared Caesar J. Belbel, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Kathleen Pozelet  
Signature of Notary Public

Place Notary Seal Above

My Commission Expires: Feb. 7, 2014

Seller Patents handled by Williams Mullen

| WM File No. | Seller File No. | Ctry | Case Type | Status | Short Title   | App. No.<br>App Date         |
|-------------|-----------------|------|-----------|--------|---|------------------------------|
| 029514.0045 | ATL-002-AR      | AR   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines Pharmaceutical Compositions... | P040103058<br>08/25/04       |
| 029514.0039 | ATL-002-AU      | AU   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 2004268964<br>03/03/06       |
| 029514.0037 | ATL-002-BR      | BR   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | P10413922-4<br>02/24/06      |
| 029514.0038 | ATL-002-CA      | CA   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 2536553<br>02/22/06          |
| 029514.0043 | ATL-002-CN      | CN   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 200480031455.4<br>04/24/06   |
| 029514.0044 | ATL-002-EP      | EP   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | EP04781752.3<br>02/14/06     |
| 029514.0069 | ATL-002-HK      | HK   |           |        | Substituted 8 - Heteroaryl Xanthines                                | 7103594.7<br>4/3/07          |
| 029514.0040 | ATL-002-IL      | IL   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 173723<br>02/14/06           |
| 029514.0041 | ATL-002-IN      | IN   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 1014/CHENP/2006<br>03/24/06  |
| 029514.0042 | ATL-002-JP      | JP   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 2006-524755<br>02/27/06      |
| 029514.0031 | ATL-002-KR      | KR   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 2006-7003776<br>02/24/06     |
| 029514.0035 | ATL-002-MX      | MX   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | PA/a/2006/002223<br>02/24/06 |
| 029514.0016 | ATL-002-NZ      | NZ   | XP2       | PEN    | Substituted 8-Heteroaryl Xanthines                                  | 545715<br>03/03/06           |
| 029514.0015 | ATL-002-PCT     | WO   | PCT       | EXP    | Substituted 8 Heteroaryl Xanthines                                  | US2004/027133<br>08/20/04    |
| 029514.0036 | ATL-002-RU      | RU   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                                | 2006109474<br>03/24/06       |

| WM File No. | Seller File No. | Ctry | Case Type | Status | Short Title   | App. No.<br>App Date       |
|-------------|-----------------|------|-----------|--------|---|----------------------------|
| 029514.0033 | ATL-002-SG      | SG   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                          | 200601005-2<br>02/15/06    |
| 029514.0034 | ATL-002-TW      | TW   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                          | 93125436<br>08/26/04       |
| 029514.0048 | ATL-002-US      | US   | NAT       | REG    | Utility - Substituted 8 - Heteroaryl Xanthines                | 10/923,592<br>08/20/04     |
| 029514.0100 | ATL-002-US2     | US   | CONT      | PEN    | Substituted 8-Heteroaryl Xanthines                            | 11/956,876<br>12/14/2007   |
| 029514.0017 | ATL-002-ZA      | ZA   | XP2       | PEN    | Substituted 8 - Heteroaryl Xanthines                          | 20062333<br>03/22/06       |
| 029514.0025 | ATL-003-AU      | AU   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 2005231440<br>09/25/06     |
| 029514.0024 | ATL-003-CA      | CA   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 2563123<br>09/29/06        |
| 029514.0022 | ATL-003-CN      | CN   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 200580017513.2<br>11/29/06 |
| 029514.0110 | ATL-003-CNT2    | US   | CONT      | PEN    | Selective Antagonists A2A Receptors                           | 12/049,801<br>3/17/08      |
| 029514.0075 | ATL-003-CON     | US   | CNT       | ABD    | Selective Antagonists A2A Adenosine Receptors                 | 11/803,312<br>5/14/07      |
| 029514.0023 | ATL-003-EP      | EP   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 5740103.6<br>11/17/06      |
| 029514.0068 | ATL-003-HK      | HK   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 0715581.7<br>5/28/07       |
| 029514.0021 | ATL-003-IL      | IL   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 178365<br>09/28/06         |
| 029514.0018 | ATL-003-IN      | IN   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 09/28/06                   |
| 029514.0020 | ATL-003-JP      | JP   | XP2       | PEN    | Selective Antagonists A2A Adenosine Receptors                 | 2007506308<br>10/02/06     |
| 029514.0019 | ATL-003-PCT     | WO   | PCT       | EXP    | Selective Antagonists A2A Adenosine Receptors                 | US2005/011078<br>04/04/05  |
| 029514.0049 | ATL-003-PR      | US   | PRO       | CLD    | Provisional 1 - Selective Antagonists A2A Adenosine Receptors | 60/559,159<br>04/02/04     |

PATENT

REEL: 025533 FRAME: 0156

| WM File No. | Seller File No. | Ctry | Case Type | Status | Short Title  | App. No.<br>App Date      |
|-------------|-----------------|------|-----------|--------|--|---------------------------|
| 029514.0051 | ATL-003-US      | US   | NAT       | REG    | Utility - Selective Antagonists A2A Adenosine Receptors                                      | 11/097,251<br>04/04/05    |
| 029514.0077 | ATL-004-PCT     | WO   | PCT       | PEN    | Substituted Arylpiperidinyalknadenosines as A2A Agonist                                      | US2007/012043<br>5/18/07  |
| 029514.0057 | ATL-004-PR      | US   | PRO       | CLD    | Provisional 1 - Substituted Aryl<br>Piperidinyalknadenosines as A2AR Agonists                | 60/794,843<br>04/26/06    |
| 029514.0058 | ATL-004-PR1     | US   | PRO       | CLD    | Provisional 2 - Substituted Aryl<br>Piperidinyalknadenosines as A2AR Agonists                | 60/747,625<br>05/18/06    |
| 029514.0076 | ATL-004-US      | US   | NAT       | PEN    | Substituted Arylpiperidinyalknadenosines as A2A Agonist                                      | 11/804,165<br>5/14/07     |
| 029514.0091 | ATL-005-PCT     | WO   | PCT       | PEN    | Substituted 8 Heteroaryl Xanthines   | US2007/013849<br>6/13/07  |
| 029514.0046 | ATL-005-PR      | US   | PRO       | CLD    | Provisional 1 - Substituted 8 - Heteroaryl Xanthines   | 60/805,030<br>06/16/06    |
| 029514.0047 | ATL-005-PR1     | US   | PRO       | CLD    | Provisional 2 - Substituted 8 - Heteroaryl Xanthines   | 60/805,564<br>06/22/06    |
| 029514.0090 | ATL-005-US      | US   | NAT       | PEN    | Substituted 8 Heteroaryl Xanthines   | 11/811,823<br>6/12/2007   |
| 029514.0027 | ATL-006-PCT     | WO   | PCT       | PEN    | Pyrazol YL Substituted Xanthines   | US2006/06748<br>02/27/06  |
| 029514.0065 | ATL-006-PR      | US   | PRO       | CLD    | Provisional - Pyrazolyl Substituted Xanthines  | 60/656,105<br>02/25/05    |
| 029514.0066 | ATL-006-US      | US   | NAT       | PEN    | Utility - Pyrazolyl Substituted Xanthines  | 11/362,393<br>02/27/06    |
| 029514.0028 | ATL-007-PCT     | WO   | PCT       | PEN    | Pyridyl Substituted Xanthines  | US2006/006745<br>02/27/06 |
| 029514.0055 | ATL-007-PR      | US   | PRO       | CLD    | Provisional - Pyridyl Substituted Xanthines  | 60/656,087<br>02/25/05    |
| 029514.0056 | ATL-007-US      | US   | NAT       | PEN    | Utility - Pyridyl Substituted Xanthines  | 11/362,387<br>02/27/06    |
| 029514.0029 | ATL-008-PCT     | WO   | PCT       | PEN    | Methods for the Synthesis of Unsymmetrical Cycloalkyl<br>Substituted Xanthines               | US2006/006838<br>02/27/06 |
| 029514.0067 | ATL-008-PR      | US   | PRO       | CLD    | Provisional - Methods for the Synthesis of<br>Unsymmetrical Cycloalkyl Substituted Xanthines | 60/656,104<br>2/25/05     |

PATENT

REEL: 025533 FRAME: 0157



| WM File No. | Seller File No. | Ctry | Case Type | Status | Short Title  | App. No.<br>App Date         |
|-------------|-----------------|------|-----------|--------|--|------------------------------|
| 029514.0054 | ATL-008-US      | US   | NAT       | PEN    | Utility - Methods for the Synthesis of Unsymmetrical Cycloalkyl Substituted Xanthines    | 11/362,390<br>10/13/06       |
| 029514.0026 | ATL-009-PCT     | WO   | PCT       | PEN    | Derivatives of 8-Substituted Xanthines   | US2006/06746<br>02/27/06     |
| 029514.0063 | ATL-009-PR      | US   | PRO       | CLD    | Provisional - Derivatives of 8 - Substituted Xanthines                                   | 60/656,086<br>02/25/06       |
| 029514.0064 | ATL-009-US      | US   | NAT       | PEN    | Utility - Derivatives of 8 - Substituted Xanthines                                       | 11/362,392<br>02/27/06       |
| 029514.0093 | ATL-010-PCT     | WO   | PCT       | PEN    | Selective Antagonist of A2A Adenosine Receptors  | PCT/US2007/016164<br>7/17/07 |
| 029514.0050 | ATL-010-PR      | US   | PRO       | CLD    | Provisional 2 - Selective Antagonists A2A Adenosine Receptors                            | 60/807,545<br>07/17/06       |
| 029514.0092 | ATL-010-US      | US   | NAT       | PEN    | Selective Antagonists of A2A Adenosine Receptors   | 11/879,133<br>7/16/07        |
| 029514.0059 | ATL-011-PR      | US   | PRO       | CLD    | Provisional - New Compositions and Methods for the Treatment of Inflammation             | 60/704,433<br>08/02/05       |
| 029514.0060 | ATL-011-US      | US   | NAT       | PEN    | Utility - New Compositions and Methods for the Treatment of Inflammation                 | 11/497,280<br>08/02/06       |
| 029514.0061 | ATL-012-PR      | US   | PRO       | CLD    | Provisional - Methods for the Synthesis of Substituted Amino Amino Uracils               | 60/711,422<br>08/26/05       |
| 029514.0062 | ATL-012-US      | US   | NAT       | PEN    | Utility - Methods for the Synthesis of Substituted Amino Uracils                         | 11/510,632<br>08/28/06       |
| 029514.0097 | ATL-014-PCT     | WO   | PCT       | PEN    | Pyrrolo[3,2-D]pyrimidines That Are Selective Antagonists of A2B Adenosine Receptors      | US2007/019266<br>9/4/07      |
| 029514.0052 | ATL-014-PR      | US   | PRO       | CLD    | Provisional - Selective Antagonists A2B Adenosine Receptors                              | 60/824,316<br>09/01/06       |
| 029514.0096 | ATL-014-US      | US   | NAT       | PEN    | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS      | 11/897,678<br>8/31/07        |
| 029514.0053 | ATL-015-PR      | US   | PRO       | CLD    | Provisional - Antagonists of A2B Adenosine Receptors for Treatment of Ulcerative Colitis | 60/829,369<br>10/13/06       |
| 029514.0014 | ATL-015-PR      | US   | PRO       | CLD    | Antagonists of A2B Adenosine Receptors for Treatment of Inflammatory Bowel Disease       | 60/878,613<br>01/04/07       |

| WMI File No. | Seller File No. | Ctry | Case Type | Status | Short Title  | App. No.<br>App Date      |
|--------------|-----------------|------|-----------|--------|--|---------------------------|
| 029514.0107  | ATL-016-PCT     | WO   | PCT       | PEN    | Agonists of A2A Adenosine Receptors for Treating Recurrent Tumor Growth in the Liver Following Resection   | US2008/060304<br>4/15/08  |
| 029514.0072  | ATL-016-PR      | US   | PRO       | CLD    | Agonists of A2A Adenosine Receptors for Treating Recurrent Tumor Growth in the Liver Following Resection   | 60925736<br>4/23/07       |
| 029514.0106  | ATL-016-US      | US   | NAT       | PEN    | Agonists of A2A Adenosine Receptors for Treating Recurrent Tumor Growth in the Liver Following Resection   | 12/102,185<br>4/14/08     |
| 029514.0102  | ATL-017-P1      | US   | PRO       | PEN    | SUBSTITUTED 4-{3-[6-AMINO-9-(3,4-DIHYDROXY-TETRAHYDRO-FURAN-2-YL)-9H-PURIN-2-YL]-PROP-2-YNYL}-PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | 61/015,303<br>12/20/2007  |
| 029514.0103  | ATL-018-P1      | US   | PRO       | PEN    | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS   | 61/019,912<br>1/09/2008   |
| 029514.0101  | ATL-019-P1      | US   | PRO       | PEN    | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES   | 61/014,134<br>12/17/2007  |
| 029514.0109  | ATL-021-P1      | US   | PRO       | PEN    | Substituted 8-[Carbonylamino-3-Pyridyl] Xanthines  | 61/046,568<br>4/21/08     |
| 029514.0105  | ATL-022-PCT     | WO   | PCT       | PEN    | Adenosine Derivative Formulations for Medical Imaging  | US2008/00549<br>1/16/2008 |
| 029514.0079  | ATL-022-PR      | US   | PRO       | EXP    | Adenosine Derivative Formulations for Medical Imaging  | 60/885,489<br>1/18/07     |
| 029514.0104  | ATL-022-US      | US   | NAT       | PEN    | Adenosine Derivative Formulations for Medical Imaging  | 12/014,949<br>1/16/2008   |
| 029514.0113  | ATL-023-P1      | US   | PRO       | PEN    | Alkoxy-Carbonyl-Amino-Alkaryl-Adenosine Compounds and Derivatives Thereof as A2AR Agonists   | 61/075,096<br>2526371     |
| 029514.0083  | ATL-7224-CA     | CA   | XP2       | PEN    | Methods for Preparing 2-Alkaryladenosine Derivatives   | 11/18/05<br>200480020486X |
| 029514.0084  | ATL-7224-CN     | CN   | XP2       | PEN    | Methods for Preparing 2-Alkaryladenosine Derivatives   | 1/10/06<br>04752741.1     |
| 029514.0085  | ATL-7224-EP     | EP   | XP2       | PEN    | Methods for Preparing 2-Alkaryladenosine Derivatives   | 11/14/05<br>06113955.0    |
| 029514.0086  | ATL-7224-HK     | HK   | XP2       | PEN    | Methods for Preparing 2-Alkaryladenosine Derivatives   | 12/19/06                  |

PATENT

REEL: 025533 FRAME: 0159

| <i>WM File No.</i> | <i>Seller File No.</i> | <i>Crty</i> | <i>Case Type</i> | <i>Status</i> | <i>Short Title</i>                                   | <i>App. No.<br/>App Date</i> |
|--------------------|------------------------|-------------|------------------|---------------|--|------------------------------|
| 029514.0087        | ATL-7224-IN            | IN          | XP2              | PEN           | Methods for Preparing 2-Alkynyladenosine Derivatives | 5180/DELNP/2005<br>11/10/05  |
| 029514.0078        | ATL-7224-JP            | JP          | XP2              | PEN           | Methods for Preparing 2-Alkynyladenosine Derivatives | 2006-533232<br>11/21/05      |
| 029514.0088        | ATL-7224-MX            | MX          | XP2              | PEN           | Methods for Preparing 2-Alkynyladenosine Derivatives | PA/a/2005/012309<br>11/15/05 |
| 029514.0080        | ATL-7224-PR            | US          | PRO              | CLD           | Methods for Preparing 2-Alkynyladenosine Derivatives | 60471643<br>5/19/03          |
| 029514.0081        | ATL-7224-US            | US          | NAT              | CLD           | Methods for Preparing 2-Alkynyladenosine Derivatives | 10848403<br>5/18/04          |
| 029514.0098        | ATL-7224-US-<br>CNT1   | US          | CONT             | PEN           | Methods for Preparing 2-Alkynyladenosine Derivatives | 11/975,080<br>10/17/2007     |
| 029514.0082        | ATL-7224-WO            | WO          | PCT              | EXP           | Methods for Preparing 2-Alkynyladenosine Derivatives | PCT/US2004/015783<br>5/19/04 |

PATENT

REEL: 025533 FRAME: 0160

RECORDED: 12/21/2010